21/07/2026
Tamiflu re think?
"Before the REMAP-CAP trial, there had never been a randomised trial of oseltamivir in the critically ill."
"These results indicate that, among critically ill patients (aged 12 or older) with confirmed influenza, treatment with oseltamivir was found to be ineffective in reducing 90-day mortality compared with no antiviral, and had a high probability of harm."
"These results do not relate to the use of oseltamivir in other populations (e.g., non-hospitalised patients, non-critically ill hospitalised patients, and children) with influenza. The use of oseltamivir in these patients should follow local guidelines."
https://www.remapcap.org/oseltamivir-clinician-faqs
My musings only
Not a Substitute for Professional Advice
The information is for general educational and informational purposes only.
Not a substitute for professional medical advice, diagnosis, or treatment.
Always seek the advice of your qualified primary healthcare provider regarding any medical condition.
Never urinate on an electric fence.
REMAP-CAP is a global Bayesian adaptive platform trial that evaluates multiple interventions for hospitalised patients with respiratory tract infection. One treatment that REMAP-CAP is evaluating are influenza antivirals, including oseltamivir, a neuraminidase inhibitor that prevents the replication...
